Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma.

Katsaounou P, Odemyr M, Spranger O, Hyland ME, Kroegel C, Conde LG, Gore R, Menzella F, Domingo Ribas C, Morais-Almeida M, Gasser M, Kasujee I.

ERJ Open Res. 2018 Dec 21;4(4). pii: 00076-2018. doi: 10.1183/23120541.00076-2018. eCollection 2018 Oct.

2.

Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.

BĂ©rard F, Ferrier Le Bouedec MC, Bouillet L, Reguiai Z, Barbaud A, Cambazard F, Milpied B, Pelvet B, Kasujee I, Gharbi H, Lacour JP.

Br J Dermatol. 2019 Jan;180(1):56-66. doi: 10.1111/bjd.16904. Epub 2018 Sep 17.

PMID:
29927483
3.

Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?

Matucci A, Vultaggio A, Maggi E, Kasujee I.

Respir Res. 2018 Jun 8;19(1):113. doi: 10.1186/s12931-018-0813-0. Review.

4.

Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.

Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I.

Respir Med. 2017 Mar;124:36-43. doi: 10.1016/j.rmed.2017.01.008. Epub 2017 Jan 25.

PMID:
28284319

Supplemental Content

Loading ...
Support Center